Bridge Bio Oncology Therapeutics

BridgeBio Oncology Therapeutics (BBOT) is a clinical-stage biopharmaceutical company developing bioavailable small-molecule inhibitors for cancers driven by RAS and PI3K pathways. Its research explores novel approaches to the RAS signaling pathway and creates RAS-targeted small molecules, including approaches to inhibit KRAS in both active and inactive states and RAS-driven PI3Kα activation. The company aims to deliver well-tolerated medicines with greater efficacy and safety for people with deadly cancers.